Literature DB >> 9856414

Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome.

J E Hall1, A E Taylor, F J Hayes, W F Crowley.   

Abstract

Polycystic ovary syndrome (PCOS) is characterized by menstrual dysfunction and hyperandrogenism in the absence of other known causes. While the pathogenesis of PCOS remains elusive and is likely to involve abnormalities in several systems, there has long been an association of abnormal gonadotropin secretion with this disorder. In recent studies we have determined that 94% of women meeting the broad criteria for PCOS have an increased LH/FSH ratio. Several lines of evidence suggest that the mechanisms underlying the increased LH/FSH ratio in PCOS include an increased frequency of GnRH secretion. Decreased sensitivity to progesterone negative feedback on the GnRH pulse generator may play a role in this neuroendocrine defect. Additional factors which may contribute to the low to normal FSH levels in the face of increased LH include chronic mild estrogen increases and possibly inhibin. In addition to these effects on the differential control of FSH, there is increased pituitary sensitivity of LH secretion to GnRH. Both estrogen and androgens have been proposed as candidates mediating these effects. Superimposed on these underlying abnormalities in gonadotropin secretion is a marked inhibitory effect of obesity on LH secretion which may be mediated at either a pituitary or hypothalamic level.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9856414     DOI: 10.1007/BF03350785

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  61 in total

Review 1.  Molecular biology of the pituitary gonadotropins.

Authors:  S D Gharib; M E Wierman; M A Shupnik; W W Chin
Journal:  Endocr Rev       Date:  1990-02       Impact factor: 19.871

Review 2.  Clinical review 94: What's in a name? In search of leptin's physiologic role.

Authors:  J S Flier
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

Review 3.  Polycystic ovary syndrome: a changing perspective.

Authors:  S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1989-07       Impact factor: 3.478

4.  Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome?

Authors:  A Dunaif
Journal:  J Clin Endocrinol Metab       Date:  1986-07       Impact factor: 5.958

5.  The frequency of gonadotropin-releasing-hormone stimulation differentially regulates gonadotropin subunit messenger ribonucleic acid expression.

Authors:  A C Dalkin; D J Haisenleder; G A Ortolano; T R Ellis; J C Marshall
Journal:  Endocrinology       Date:  1989-08       Impact factor: 4.736

Review 6.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

7.  Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome.

Authors:  L Corenthal; S Von Hagen; D Larkins; J Ibrahim; N Santoro
Journal:  Fertil Steril       Date:  1994-06       Impact factor: 7.329

8.  Increased luteinizing hormone and alpha-subunit secretion in women with hyperandrogenic anovulation.

Authors:  S L Berga; D S Guzick; S J Winters
Journal:  J Clin Endocrinol Metab       Date:  1993-10       Impact factor: 5.958

9.  Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome.

Authors:  H M Buckler; S E Phillips; I T Cameron; D L Healy; H G Burger
Journal:  J Clin Endocrinol Metab       Date:  1988-08       Impact factor: 5.958

10.  Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO.

Authors:  R A Lobo; L Granger; U Goebelsmann; D R Mishell
Journal:  J Clin Endocrinol Metab       Date:  1981-01       Impact factor: 5.958

View more
  21 in total

Review 1.  GnRH signaling, the gonadotrope and endocrine control of fertility.

Authors:  Stuart P Bliss; Amy M Navratil; Jianjun Xie; Mark S Roberson
Journal:  Front Neuroendocrinol       Date:  2010-05-06       Impact factor: 8.606

Review 2.  The biology of gonadotroph regulation.

Authors:  Nick A Ciccone; Ursula B Kaiser
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-08       Impact factor: 3.243

Review 3.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

4.  c-JUN Dimerization Protein 2 (JDP2) Is a Transcriptional Repressor of Follicle-stimulating Hormone β (FSHβ) and Is Required for Preventing Premature Reproductive Senescence in Female Mice.

Authors:  Carrie R Jonak; Nancy M Lainez; Lacey L Roybal; Alexa D Williamson; Djurdjica Coss
Journal:  J Biol Chem       Date:  2016-12-22       Impact factor: 5.157

5.  Rescue of obesity-induced infertility in female mice due to a pituitary-specific knockout of the insulin receptor.

Authors:  Kathryn J Brothers; Sheng Wu; Sara A DiVall; Marcus R Messmer; C Ronald Kahn; Ryan S Miller; Sally Radovick; Fredric E Wondisford; Andrew Wolfe
Journal:  Cell Metab       Date:  2010-09-08       Impact factor: 27.287

6.  Progesterone treatment inhibits and dihydrotestosterone (DHT) treatment potentiates voltage-gated calcium currents in gonadotropin-releasing hormone (GnRH) neurons.

Authors:  Jianli Sun; Suzanne M Moenter
Journal:  Endocrinology       Date:  2010-08-25       Impact factor: 4.736

7.  A single-nucleotide polymorphism in the EAP1 gene is associated with amenorrhea/oligomenorrhea in nonhuman primates.

Authors:  Alejandro Lomniczi; Cecilia Garcia-Rudaz; Ranjani Ramakrishnan; Beth Wilmot; Samone Khouangsathiene; Betsy Ferguson; Gregory A Dissen; Sergio R Ojeda
Journal:  Endocrinology       Date:  2011-11-29       Impact factor: 4.736

8.  GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.

Authors:  F Orio; S Palomba; A Colao; T Russo; C Dentico; L Tauchmanovà; S Savastano; C Nappi; C Sultan; F Zullo; G Lombardi
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

Review 9.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

10.  Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans.

Authors:  Gregory A Dissen; Cecilia Garcia-Rudaz; Alfonso Paredes; Christine Mayer; Artur Mayerhofer; Sergio R Ojeda
Journal:  Endocrinology       Date:  2009-03-05       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.